Last reviewed · How we verify
International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.
Details
| Lead sponsor | Eli Lilly and Company |
|---|---|
| Status | APPROVED_FOR_MARKETING |
Conditions
- Metastatic Gastric Cancer
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
Interventions
- Ramucirumab
Countries
Netherlands, Greece, Austria, Germany, South Korea